Monoclonal gammopathy in systemic lupus erythematosus is associated with distinctive clinical course, malignancy and mortality rate: a single-centre retrospective cohort study

被引:0
作者
Siwiec-Kozlik, Andzelika [1 ,2 ]
Kozlik-Siwiec, Pawel [1 ,3 ]
Spalkowska, Magdalena [4 ]
Korkosz, Mariusz [1 ,2 ]
Kosalka-Wegiel, Joanna [1 ,2 ]
机构
[1] Jagiellonian Univ Med Coll, Dept Internal Med 2, Krakow, Poland
[2] Univ Hosp, Rheumatol & Immunol Clin Dept, Krakow, Poland
[3] Univ Hosp Krakow, Dept Clin Hematol, Krakow, Poland
[4] Univ Hosp, Dept Dermatol, Krakow, Poland
来源
LUPUS SCIENCE & MEDICINE | 2024年 / 11卷 / 02期
关键词
Systemic Lupus Erythematosus; Hematology; Risk Factors; Cause of Death; B-Lymphocytes; MULTIPLE-MYELOMA; CRITERIA; CLASSIFICATION; PREVALENCE; DISORDERS; DIAGNOSIS; CELLS;
D O I
10.1136/lupus-2024-001248
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives Rheumatic diseases were previously associated with increased incidence of monoclonal gammopathy (MG) and its malignant transformation. The present study aimed to investigate the prevalence, malignant transformation risk, clinical correlates and prognostic impact of MG in SLE. Methods A retrospective cohort study based on the medical records of n=1039 patients with SLE fulfilling the 1997 American College of Rheumatology (ACR), the 2019 European Alliance of Associations for Rheumatology (EULAR)/ACR and/or the 2012 Systemic Lupus International Collaborating Clinics (SLICC) criteria managed at two tertiary care departments of the University Hospital (Krakow, Poland) from January 2012 until November 2019. Results SLE+MG cases were older at SLE diagnosis compared with non-MG SLE controls (53 +/- 15 years vs 37 +/- 15 years, respectively, p<0.01), had higher rates of lymphopenia, anaemia, haemolysis, serous effusions and interstitial lung disease (all p<0.05), and were more frequently treated with cyclophosphamide (57% vs 28%, p<0.01) or rituximab (13% vs 3%, p<0.01). Most MG cases were detected within a year after SLE diagnosis (Q25, Q75: 0, 12 years). With the median follow-up of 11 years (Q25, Q75: 6, 19 years), 34.8% (8 cases) of the SLE+MG cohort were diagnosed with malignancy, compared with 8.1% (82 cases) among the SLE controls (p<0.001). MG was associated with the relative hazard of death of HR 2.99 (95% CI 1.26 to 7.06, p<0.05) and a median survival time from SLE diagnosis to death of 5 years (Q25, Q75: 1, 14; range 0-41) for SLE+MG cases, as compared with 12 years (Q25, Q75: 6, 19; range 0-62) for the controls. The effect was non-independent on antimalarial medication use. Conclusions Our study emphasises heightened malignancy and mortality rates in SLE+MG cases. The association between immunosuppression, MG incidence and progression warrants further research.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 32 条
  • [11] Prevalence of monoclonal gammopathy in HIV patients in 2014
    Genet, Philippe
    Sutton, Laurent
    Chaoui, Driss
    Al Jijakli, Ahmad
    Gerbe, Juliette
    Masse, Virginie
    Wifaq, Bouchra
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2014, 17 : 103 - 104
  • [12] Monoclonal gammopathy in patients with B cell immunodeficiency
    Herzog, R
    Rubinstein, A
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (02) : S110 - S110
  • [13] Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus
    Hochberg, MC
    [J]. ARTHRITIS AND RHEUMATISM, 1997, 40 (09): : 1725 - 1725
  • [14] Treg and Oligoclonal Expansion of Terminal Effector CD8+ T Cell as Key Players in Multiple Myeloma
    Joshua, Douglas E.
    Vuckovic, Slavica
    Favaloro, James
    Lau, Ka Hei Aleks
    Yang, Shihong
    Bryant, Christian E.
    Gibson, John
    Ho, Phoebe Joy
    [J]. FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [15] Association between senescence of T cells and disease activity in patients with systemic lupus erythematosus
    Kalim, Handono
    Wahono, Cesarius Singgih
    Permana, Bunga Petriana Oktarini
    Pratama, Mirza Zaka
    Handono, Kusworini
    [J]. REUMATOLOGIA, 2021, 59 (05): : 292 - 301
  • [16] IgM monoclonal gammopathies of clinical significance: diagnosis and management
    Khwaja, Jahanzaib
    D'Sa, Shirley
    Minnema, Monique C.
    Kersten, Marie Jose
    Wechalekar, Ashutosh
    Vos, Josephine M., I
    [J]. HAEMATOLOGICA, 2022, 107 (09) : 2037 - 2050
  • [17] Kyle RA, 2003, BRIT J HAEMATOL, V121, P749
  • [18] Prevalence of monoclonal gammopathy of undetermined significance
    Kyle, RA
    Therneau, TM
    Rajkumar, SV
    Larson, DR
    Plevak, MF
    Offord, JR
    Dispenzieri, A
    Katzmann, JA
    Melton, LJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (13) : 1362 - 1369
  • [19] Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study
    Kyle, Robert A.
    Larson, Dirk R.
    Therneau, Terry M.
    Dispenzieri, Angela
    Melton, L. Joseph, III
    Benson, Joanne T.
    Kumar, Shaji
    Rajkumar, S. Vincent
    [J]. LANCET HAEMATOLOGY, 2014, 1 (01): : E28 - E36
  • [20] Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12 372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey
    Landgren, O.
    Graubard, B. I.
    Kumar, S.
    Kyle, R. A.
    Katzmann, J. A.
    Murata, K.
    Costello, R.
    Dispenzieri, A.
    Caporaso, N.
    Mailankody, S.
    Korde, N.
    Hultcrantz, M.
    Therneau, T. M.
    Larson, D. R.
    Cerhan, J. R.
    Rajkumar, S. V.
    [J]. BLOOD CANCER JOURNAL, 2017, 7 : e618 - e618